Literature DB >> 26438122

Towards a balanced approach to identifying conflicts of interest faced by institutional review boards.

Sharon Kaur1, Sujata Balan2.   

Abstract

The welfare and protection of human subjects is critical to the integrity of clinical investigation and research. Institutional review boards (IRBs) were thus set up to be impartial reviewers of research protocols in clinical research. Their main role is to stand between the investigator and her human subjects in order to ensure that the welfare of human subjects are protected. While there is much literature on the conflicts of interest (CIs) faced by investigators and researchers in clinical investigations, an area that is less explored is CIs that may affect members of IRBs during the institutional ethics review of clinical investigations. This article examines the notion of CIs in clinical research and attempts to develop a framework for a clearer and more balanced approach to identifying CIs that may influence members of IRBs and impede their independence. It will also apply the proposed framework to demonstrate how IRBs possess, or at least may appear to possess, forms of financial CIs and non-financial CIs. The proper identification and management of these CIs is critical to preserving the integrity of clinical investigations and achieving the primary aim of human subjects protection.

Entities:  

Keywords:  Clinical research; Conflicts of interests (CIs); Institutional review boards (IRBs)

Mesh:

Year:  2015        PMID: 26438122     DOI: 10.1007/s11017-015-9339-3

Source DB:  PubMed          Journal:  Theor Med Bioeth        ISSN: 1386-7415


  25 in total

1.  Ethics review for sale? Conflict of interest and commercial research review boards.

Authors:  T Lemmens; B Freedman
Journal:  Milbank Q       Date:  2000       Impact factor: 4.911

2.  Financial conflict of interest: an unresolved ethical frontier.

Authors:  J P Kassirer
Journal:  Am J Law Med       Date:  2001

Review 3.  Scope and impact of financial conflicts of interest in biomedical research: a systematic review.

Authors:  Justin E Bekelman; Yan Li; Cary P Gross
Journal:  JAMA       Date:  2003 Jan 22-29       Impact factor: 56.272

4.  Financial relationships between institutional review board members and industry.

Authors:  Eric G Campbell; Joel S Weissman; Christine Vogeli; Brian R Clarridge; Melissa Abraham; Jessica E Marder; Greg Koski
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

5.  Managing conflicts of interest in the conduct of clinical trials.

Authors:  Karine Morin; Herbert Rakatansky; Frank A Riddick; Leonard J Morse; John M O'Bannon; Michael S Goldrich; Priscilla Ray; Matthew Weiss; Robert M Sade; Monique A Spillman
Journal:  JAMA       Date:  2002-01-02       Impact factor: 56.272

6.  The participation of community members on medical institutional review boards.

Authors:  Charles W Lidz; Lorna J Simon; Antonia V Seligowski; Suzanne Myers; William Gardner; Philip J Candilis; Robert Arnold; Paul S Appelbaum
Journal:  J Empir Res Hum Res Ethics       Date:  2012-02       Impact factor: 1.742

7.  Understanding financial conflicts of interest.

Authors:  D F Thompson
Journal:  N Engl J Med       Date:  1993-08-19       Impact factor: 91.245

8.  The new medical-industrial complex.

Authors:  A S Relman
Journal:  N Engl J Med       Date:  1980-10-23       Impact factor: 91.245

9.  Quality of informed consent in cancer clinical trials: a cross-sectional survey.

Authors:  S Joffe; E F Cook; P D Cleary; J W Clark; J C Weeks
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

10.  Professional integrity in clinical research.

Authors:  F G Miller; D L Rosenstein; E G DeRenzo
Journal:  JAMA       Date:  1998-10-28       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.